Q2 EPS Estimate for Aclaris Therapeutics Raised by Analyst

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – HC Wainwright upped their Q2 2026 earnings estimates for Aclaris Therapeutics in a note issued to investors on Monday, May 11th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.12) per share for the quarter, up from their prior estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.51) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 832.58% and a negative return on equity of 55.89%. The company had revenue of $2.00 million during the quarter, compared to analyst estimates of $1.32 million.

Several other equities analysts also recently issued reports on ACRS. Piper Sandler upped their price objective on shares of Aclaris Therapeutics from $7.00 to $11.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. UBS Group set a $10.00 price objective on shares of Aclaris Therapeutics in a research note on Thursday, April 16th. Wedbush raised their price objective on shares of Aclaris Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Oppenheimer began coverage on shares of Aclaris Therapeutics in a research note on Thursday, April 16th. They issued an “outperform” rating and a $10.00 price target on the stock. Finally, Craig Hallum began coverage on Aclaris Therapeutics in a report on Friday, January 30th. They issued a “buy” rating and a $10.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $11.29.

Aclaris Therapeutics Stock Performance

ACRS stock opened at $4.88 on Wednesday. The firm has a market cap of $681.54 million, a price-to-earnings ratio of -8.71 and a beta of 0.76. The firm has a 50-day simple moving average of $3.94 and a two-hundred day simple moving average of $3.32. Aclaris Therapeutics has a one year low of $1.16 and a one year high of $5.12.

Institutional Trading of Aclaris Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP raised its holdings in Aclaris Therapeutics by 88.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock valued at $1,914,000 after buying an additional 240,611 shares during the period. Bank of New York Mellon Corp raised its holdings in Aclaris Therapeutics by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company’s stock valued at $776,000 after buying an additional 3,507 shares during the period. Strs Ohio purchased a new stake in Aclaris Therapeutics in the 1st quarter valued at about $60,000. Assenagon Asset Management S.A. raised its holdings in Aclaris Therapeutics by 14.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 177,283 shares of the biotechnology company’s stock valued at $665,000 after buying an additional 22,729 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Aclaris Therapeutics by 73.6% in the 1st quarter. SG Americas Securities LLC now owns 26,767 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 11,344 shares during the period. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Aclaris Therapeutics

In related news, major shareholder Braden Michael Leonard sold 300,000 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $4.53, for a total value of $1,359,000.00. Following the sale, the insider directly owned 13,950,000 shares in the company, valued at approximately $63,193,500. The trade was a 2.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.60% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.